The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Progression of fibrosing interstitial lung disease
Open accessAbstract
Fibrotic interstitial lung diseases (ILDs) are often challenging to diagnose and classify, but an accurate diagnosis has significant implications for both treatment and prognosis. A subset of patients with fibrotic ILD experience progressive deterioration in lung function, physical performance, and quality of life. Several risk factors for ILD progression have been reported, such as male sex, older age, lower baseline pulmonary function, and a radiological or pathological pattern of usual interstitial pneumonia. Morphological similarities, common underlying pathobiologic mechanisms, and the consistently progressive worsening of these patients support the concept of a progressive fibrosing (PF)-ILD phenotype that can be applied to a variety of ILD subtypes. The conventional approach has been to use antifibrotic medications in patients with idiopathic pulmonary fibrosis (IPF) and immunosuppressive medications in patients with other fibrotic ILD subtypes; however, recent clinical trials have suggested a favourable treatment response to antifibrotic therapy in a wider variety of fibrotic ILDs. This review summarizes the literature on the evaluation and management of patients with PF-ILD, and discusses questions relevant to applying recent clinicial trial findings to real-world practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Nintedanib for systemic sclerosis–associated interstitial lung disease
Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903076 · Cited by 1,647
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Hoyles, R. K., Ellis, R. W., Wellsbury, J., Lees, B., Newlands, P., Goh, N. S. L., Roberts, C., Desai, S., Herrick, A. L., McHugh, N. J., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22204 · Cited by 732
Cited by
Progressive pulmonary fibrosis: an expert group consensus statement
Rajan, S. K., Cottin, V., Dhar, R., Danoff, S., Flaherty, K. R., Brown, K. K., Mohan, A., Renzoni, E., Mohan, M., Udwadia, Z., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.03187-2021 · Cited by 258
Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms
Montero, P., Milara, J., Roger, I., & Cortijo, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126211 · Cited by 254
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
Richeldi, L., Azuma, A., Cottin, V., Hesslinger, C., Stowasser, S., Valenzuela, C., Wijsenbeek, M. S., Zoz, D. F., Voss, F., & Maher, T. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201737 · Cited by 236
Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice
Han, M.-M., He, X.-Y., Tang, L., Qi, L., Yang, M.-Y., Wang, Y., Xing, L., Jeong, J.-H., & Jiang, H.-L. (2023) · Science Advances · doi:10.1126/sciadv.adg5358 · Cited by 86
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
Kolb, M., Crestani, B., & Maher, T. M. (2023) · European Respiratory Review · doi:10.1183/16000617.0206-2022 · Cited by 85
Metadata
- Authors
- Wong, A. W., Ryerson, C. J., & Guler, S. A.
- Venue
- Respiratory Research
- Published
- 2020-01-29
- Volume
- 21
- Issue
- 1
- Pages
- 32-32
- ISSN
- 1465-9921 (ISSN-L)
- 1465-993X
- OpenAlex
- W3006532268
- Cited by
- 185
- References
- 15
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progression of fibrosing interstitial lung disease. https://app.cochat.ai/papers/10.1186/s12931-020-1296-3
- The paper
- Wong, A. W., Ryerson, C. J., & Guler, S. A. (2020). Progression of fibrosing interstitial lung disease. Respiratory Research. https://doi.org/10.1186/s12931-020-1296-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.